<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03323671</url>
  </required_header>
  <id_info>
    <org_study_id>27011975</org_study_id>
    <nct_id>NCT03323671</nct_id>
  </id_info>
  <brief_title>Preemptive Analgesia for Primary Dysmenorrhoea</brief_title>
  <official_title>Preemptive Analgesia for Primary Dysmenorrhoea: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanan Nabil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preemptive analgesia before the release of pain mediators
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      spasmodic dysmenorrhea is one of the most distressing symptoms in women. adolescents shows a
      usual absence from school . prostaglandin release is one of the most accepted theory
      responsible for spasmodic dysmenorrhea.

      Non steroidal anti inflammatory Drugs were proved to be one of the alternative medications
      for spasmodic dysmenorrhea.

      Getting the idea of what is called preemptive anesthesia by blocking the receptors before
      catching pain mediators the study participants will be divided randomly into 2 group group 1
      receiving ttt 2 days before the anticipated menstruation and group 2 receiving ttt only
      during menstruation as analgesia
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">December 1, 2017</completion_date>
  <primary_completion_date type="Actual">December 1, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in the Degree of pain</measure>
    <time_frame>4 months</time_frame>
    <description>severity of pain according to visual pain analog scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Primary Dysmenorrhea</condition>
  <arm_group>
    <arm_group_label>premenstruation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>preemptive mefenamic acid 500mg tablets every 8 hours starting 2 days before anticipated menstruation and during the first 2 days of the cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>menstruation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mefenamic acid 500mg tablets every 8 hours during the first 2 days of the cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>preemptive mefenamic acid</intervention_name>
    <description>preemptive analgesia before menstrual pain</description>
    <arm_group_label>premenstruation group</arm_group_label>
    <other_name>ponstan forte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mefenamic acid</intervention_name>
    <description>mefenamic acid given only during menstruation</description>
    <arm_group_label>menstruation group</arm_group_label>
    <other_name>ponstan forte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  nulliparous ladies

          -  with regular menstrual cycle pattern

          -  those experienced history of dysmenorrhea (primary or spasmodic)

          -  patients able to sallow tables

        Exclusion Criteria:

          -  irregular cycles

          -  any associated local causes( pelvic infection, endometriosis, fibroid or others)

          -  patients with familial Mediterranean fever or other intermenstrual attacks of
             abdominal pain

          -  gastric or duodenal ulcers or gastritis

          -  other contraindications to non steroidal anti-inflammatory drugs

          -  patients with severe diminution of vision or color discrimination

          -  patients with any depressive or mood disorders

          -  patients receiving any hormonal treatment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanan Nabil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manoura University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mansoura University</name>
      <address>
        <city>Mansourah</city>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2015</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2017</study_first_posted>
  <last_update_submitted>December 17, 2017</last_update_submitted>
  <last_update_submitted_qc>December 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Hanan Nabil</investigator_full_name>
    <investigator_title>Associate Professor Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <keyword>primary dysmenorrhea</keyword>
  <keyword>preemptive analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mefenamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

